Recommendations for the Use of Methotrexate in Rheumatoid Arthritis: Up and Down Scaling of the Dose and Administration Routes

array:23 ["pii" => "S2173574314000872" "issn" => "21735743" "doi" => "10.1016/j.reumae.2014.02.006" "estado" => "S300" "fechaPublicacion" => "2015-01-01" "aid" => "667" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2013" "documento" => "article" "subdocumento" => "fla" "cita" => "Reumatol Clin. 2015;11:3-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3501 "formatos" => array:3 [ "EPUB" => 60 "HTML" => 2861 "PDF" => 580 ] ] "Traduccion" => array:1 [ "es" => array:18 [ "pii" => "S1699258X1400059X" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2014.02.012" "estado" => "S300" "fechaPublicacion" => "2015-01-01" "aid" => "667" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "subdocumento" => "fla" "cita" => "Reumatol Clin. 2015;11:3-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 34156 "formatos" => array:3 [ "EPUB" => 206 "HTML" => 29372 "PDF" => 4578 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "Artículo especial" "titulo" => "Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "3" "paginaFinal" => "8" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Recommendations for the use of methotrexate in rheumatoid arthritis: Up and down scaling of the dose and administration routes" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2094 "Ancho" => 2490 "Tamanyo" => 255921 ] ] "descripcion" => array:1 [ "es" => "Selección de citas bibliográficas realizada desde la búsqueda inicial hasta la redacción del artículo." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jesús Tornero Molina, Francisco Javier Ballina García, Jaime Calvo Alén, Miguel Ángel Caracuel Ruiz, Jordi Carbonell Abelló, Antonio López Meseguer, José Vicente Moreno Muelas, Trinidad Pérez Sandoval, Jesús Quijada Carrera, Pilar Trenor Larraz, Antonio Zea Mendoza" "autores" => array:11 [ 0 => array:2 [ "nombre" => "Jesús" "apellidos" => "Tornero Molina" ] 1 => array:2 [ "nombre" => "Francisco Javier" "apellidos" => "Ballina García" ] 2 => array:2 [ "nombre" => "Jaime" "apellidos" => "Calvo Alén" ] 3 => array:2 [ "nombre" => "Miguel Ángel" "apellidos" => "Caracuel Ruiz" ] 4 => array:2 [ "nombre" => "Jordi" "apellidos" => "Carbonell Abelló" ] 5 => array:2 [ "nombre" => "Antonio" "apellidos" => "López Meseguer" ] 6 => array:2 [ "nombre" => "José Vicente" "apellidos" => "Moreno Muelas" ] 7 => array:2 [ "nombre" => "Trinidad" "apellidos" => "Pérez Sandoval" ] 8 => array:2 [ "nombre" => "Jesús" "apellidos" => "Quijada Carrera" ] 9 => array:2 [ "nombre" => "Pilar" "apellidos" => "Trenor Larraz" ] 10 => array:2 [ "nombre" => "Antonio" "apellidos" => "Zea Mendoza" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574314000872" "doi" => "10.1016/j.reumae.2014.02.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314000872?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X1400059X?idApp=UINPBA00004M" "url" => "/1699258X/0000001100000001/v2_201706020231/S1699258X1400059X/v2_201706020231/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2173574314001129" "issn" => "21735743" "doi" => "10.1016/j.reumae.2014.03.020" "estado" => "S300" "fechaPublicacion" => "2015-01-01" "aid" => "672" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "subdocumento" => "crp" "cita" => "Reumatol Clin. 2015;11:9-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2574 "formatos" => array:3 [ "EPUB" => 64 "HTML" => 2190 "PDF" => 320 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Brief report" "titulo" => "Is It Safe to Perform Joint Infiltrations or Aspirations in Patients Anticoagulated With Acenocoumarol?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "9" "paginaFinal" => "11" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Es seguro realizar infiltraciones o aspiraciones articulares en pacientes anticoagulados con acenocumarol?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carlos Guillen Astete, Alina Boteanu, Carmen Medina Quiñones, Nuria Garcia Montes, Fernando Roldan Moll, César Carballo Carmano, Antonio Zea Mendoza" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Carlos" "apellidos" => "Guillen Astete" ] 1 => array:2 [ "nombre" => "Alina" "apellidos" => "Boteanu" ] 2 => array:2 [ "nombre" => "Carmen" "apellidos" => "Medina Quiñones" ] 3 => array:2 [ "nombre" => "Nuria" "apellidos" => "Garcia Montes" ] 4 => array:2 [ "nombre" => "Fernando" "apellidos" => "Roldan Moll" ] 5 => array:2 [ "nombre" => "César" "apellidos" => "Carballo Carmano" ] 6 => array:2 [ "nombre" => "Antonio" "apellidos" => "Zea Mendoza" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X14000801" "doi" => "10.1016/j.reuma.2014.03.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X14000801?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314001129?idApp=UINPBA00004M" "url" => "/21735743/0000001100000001/v1_201501160858/S2173574314001129/v1_201501160858/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2173574315000040" "issn" => "21735743" "doi" => "10.1016/j.reumae.2014.09.004" "estado" => "S300" "fechaPublicacion" => "2015-01-01" "aid" => "720" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "subdocumento" => "sco" "cita" => "Reumatol Clin. 2015;11:1-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1521 "formatos" => array:3 [ "EPUB" => 59 "HTML" => 1193 "PDF" => 269 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Editorial" "titulo" => "Autoimmune flares. The hows, whens, and whys of killing" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "1" "paginaFinal" => "2" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cómo, cuando y por qué matar durante los brotes en las enfermedades autoinmunes" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Olga Sánchez-Pernaute" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Olga" "apellidos" => "Sánchez-Pernaute" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1699258X1400206X" "doi" => "10.1016/j.reuma.2014.09.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X1400206X?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574315000040?idApp=UINPBA00004M" "url" => "/21735743/0000001100000001/v1_201501160858/S2173574315000040/v1_201501160858/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "Special Article" "titulo" => "Recommendations for the Use of Methotrexate in Rheumatoid Arthritis: Up and Down Scaling of the Dose and Administration Routes" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "3" "paginaFinal" => "8" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jesús Tornero Molina, Francisco Javier Ballina García, Jaime Calvo Alén, Miguel Ángel Caracuel Ruiz, Jordi Carbonell Abelló, Antonio López Meseguer, José Vicente Moreno Muelas, Trinidad Pérez Sandoval, Jesús Quijada Carrera, Pilar Trenor Larraz, Antonio Zea Mendoza" "autores" => array:11 [ 0 => array:4 [ "nombre" => "Jesús" "apellidos" => "Tornero Molina" "email" => array:1 [ 0 => "jtorneromolina@ser.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Francisco Javier" "apellidos" => "Ballina García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Jaime" "apellidos" => "Calvo Alén" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Miguel Ángel" "apellidos" => "Caracuel Ruiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Jordi" "apellidos" => "Carbonell Abelló" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Antonio" "apellidos" => "López Meseguer" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "f" "identificador" => "aff0030" ] ] ] 6 => array:3 [ "nombre" => "José Vicente" "apellidos" => "Moreno Muelas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "g" "identificador" => "aff0035" ] ] ] 7 => array:3 [ "nombre" => "Trinidad" "apellidos" => "Pérez Sandoval" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "h" "identificador" => "aff0040" ] ] ] 8 => array:3 [ "nombre" => "Jesús" "apellidos" => "Quijada Carrera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "i" "identificador" => "aff0045" ] ] ] 9 => array:3 [ "nombre" => "Pilar" "apellidos" => "Trenor Larraz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "j" "identificador" => "aff0050" ] ] ] 10 => array:3 [ "nombre" => "Antonio" "apellidos" => "Zea Mendoza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "k" "identificador" => "aff0055" ] ] ] ] "afiliaciones" => array:11 [ 0 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital de Guadalajara, Guadalajara, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Sierrallana, Torrelavega, Cantabria, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Reina Sofía, Córdoba, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital del Mar, Barcelona, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Gutiérrez Ortega, Valdepeñas, Ciudad Real, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Vall d’Hebron, Barcelona, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Servicio de Reumatología, Complejo Asistencia Universitario de León, León, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Virgen del Rocío, Sevilla, Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Clínico Universitario de Valencia, Valencia, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] 10 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, Spain" "etiqueta" => "k" "identificador" => "aff0055" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2094 "Ancho" => 2491 "Tamanyo" => 250662 ] ] "descripcion" => array:1 [ "en" => "Selection of citations made from the initial search to the writing of the article." ] ] ] "textoCompleto" => "IntroductionThe correct use of disease-modifying antirheumatic drugs (DMARDs) has improved the prognosis of RA based on its early use and setting a specific therapeutic goal, aiming to reach remission or the lowest possible degrees of inflammatory activity.<a class="elsevierStyleCrossRefs" href="#bib0005">1–3</a> In this sense, EULAR recommends that DMARD treatment should begin as soon as the diagnosis of RA is made.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>Methotrexate (MTX) has been used for over 20 years in the treatment of rheumatoid arthritis. The features that make the MTX as the DMARD of first choice are related to its low price, its favorable safety profile, its slowing of radiographic progression, clinical experience with high response rates, therapeutic continuity, availability and versatility of doses and routes of administration. Thus, after the diagnosis of the disease, it is indicated as the first-line treatment for early and in clearly defined RA, as recommended by different societies<a class="elsevierStyleCrossRefs" href="#bib0020">4–6</a>, and it is also suitable as an anchor drug for combination therapies.<a class="elsevierStyleCrossRef" href="#bib0035">7</a>However, there is a large variability in the clinical practice in our country with regard to the starting dose, the rate and pattern of dose escalation, selection of routes of administration and dosing with concomitant use of folic acid or folinic acid in patients with RA. This is because the clinical practice may not be clearly supported by appropriate clinical trials.The objective of this study is to establish recommendations for decision-making in the treatment of adult RA with MTX, based on scientific evidence.Materials and MethodsFor the preparation of the consensus document a group of experts, who drafted the recommendations (ER), was made up by 11 rheumatologists from hospitals of the Spanish National Health System. The ER worked according to the methodological basis given by the Quality Plan of the Ministry of Health, in its reference document “Development of clinical practice guidelines in the National Health System”.<a class="elsevierStyleCrossRef" href="#bib0040">8</a>The ER work in the context of the use of MTX in the treatment of adult RA was performed with a participatory and structured methodology, in which ER members identified 3 major blocks: (a) indication criteria; (b) initial dose and route of administration and changes along the treatment; (c) criteria for dose modification and withdrawal of MTX. A detailed index was established to solve clinical questions, to which they later applied the PICO methodology, in order to facilitate and manage the process of literature search and the subsequent development of specific recommendations developed in response to each issue raised. The systematic review of the literature was used as the basic source of the original query, clinical trials, cohort studies, protocols, review articles and clinical guidelines. Filter criteria and the search limits were established by the ER panel. The objective of all of this was to make feasible an updated and critical reading of the key aspects of the scientific evidence available. A search for articles published since 1995 was conducted, both in English and Spanish, in databases such as PubMed, Cochrane Bookseller, Trip data base and abstracts of the congresses of the Spanish Society of Rheumatology (2005–2012), The European League Against Rheumatism (2012) and the American College of Rheumatology (2010–2011) and in the latest update available for MTX data sheets for both oral and parenteral formulations (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).<elsevierMultimedia ident="fig0005"></elsevierMultimedia>The initial search result yielded 1241 articles. Relevant articles were selected in 2 phases. The first prioritized titles and abstracts (177), and the second prioritized consensus statements, specific systematic reviews and most recent articles (46). The ER panel considered necessary, in very specific cases, a complementary search in certain areas of therapeutic care, which were not sufficiently defined in the initial search strategy (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Because of the predominance of review articles and clinical guidelines, references to the summary report of the literature were expanded to a total of 182 citations.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>The categorization of levels of evidence (LE) and degrees of recommendation (DR) was performed from system criteria Scottish Intercollegiate Guidelines Network (SIGN)<a class="elsevierStyleCrossRef" href="#bib0045">9</a> themes that used diagnostic criteria of the “Center-based medicine evidence of Oxford “(CMBE). For recommendations that already had NE and/or in other previous documents DR originals are kept, referencing it in each case.The executive summary of the evidence was assessed in a participatory classroom session, in which 37 recommendations and 14 were proposed evidence. This document was sent to the ER members for their individual assessment and to vote on their agreement, to regard these recommendations as appropriate responses to the clinical questions posed. Finally, 12 recommendations reached an agreement (A) greater than 70% were established as validated formal recommendations.ResultsFrom the literature search and the articles referred, prioritized by the ER members specifically, this document regarding answers to clinical questions raised was developed, with the objective to reduce the variability in the use of MTX in the treatment of adult RA. The 12 recommendations that reached greater agreement among members of the ER panel are here presented. Of these, 10 have their scientific basis in 28 of the references cited, while 2 correspond to recommendations based from experience and expert opinion of the ER panel.What Dose Methotrexate Should be Initiated in the Treatment of Rheumatoid Arthritis?It is known that the effectiveness of MTX is dose dependent. Results of some studies indicate that an initial dose of 7.5mg/week was often ineffective and, in many cases required an increase in dose after 6 weeks.<a class="elsevierStyleCrossRefs" href="#bib0050">10,11</a> In addition, a starting dose of 12.5–20mg/week was more effective than 5–7.5mg/week, with no differences in safety.<a class="elsevierStyleCrossRef" href="#bib0060">12</a> Therefore, some experts recommend a minimum initial dose of at least 10mg/week, although it is more complicated to establish agreement on what to recommend as an optimal initial dose. However, a systematic review<a class="elsevierStyleCrossRef" href="#bib0065">13</a> defends the optimal initial dose of 10–15mg/week orally, taking into account the specific characteristics of each patient. Based on these evidences, a dose not lower than 10mg/week is recommended; but also lower doses may be considered depending on the circumstances of the patient (comorbidities, low weight, age, renal function, liver).Recommendation 1: For RA, a starting dose of MTX not less than 10mg/week should be determined, based on the severity of the disease and prognostic factors associated with the patient<a class="elsevierStyleCrossRef" href="#bib0070">14</a> (LE: 1b/2 [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075">15</a> DR: C [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075">15</a> A: 82%).What Route of Administration Should Methotrexate be Initially Delivered Through?The selection of the initial route of administration may be agreed upon between the doctor and the patient. Generally, the patient usually prefers the oral route. Different studies show that the relative bioavailability of oral MTX compared to the intramuscular MTX is good at low doses but decreases at higher doses (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRefs" href="#bib0080">16–18</a> Considering that the relationship between oral bioavailability and parenteral dosage is 1 for total doses of 7.5mg, it becomes 0.85 (range 0.77–0.93) when the total dosage reaches 10–15mg and drops to 0.64 (range 0.21–0.94) at doses of 15–20mg.Therefore, a dosage under 20mg/week, ease of handling and low cost of oral MTX position it as the preferred route of administration in RA<a class="elsevierStyleCrossRef" href="#bib0070">14</a>; however, after 15mg/week there is no evidence that the oral route is better than parenteral.However, there are situations in which to consider the parenteral route as the route of choice from the start: polypharmacy patients who are overweight or obese (as administered doses are higher), low compliance, per patient preference in order to reduce certain gastrointestinal adverse effects or to avoid medication errors. In addition, experimental data seem to indicate that the subcutaneous (sc) onset is especially useful in patients with active, longstanding disease (DAS 28≥4).<a class="elsevierStyleCrossRef" href="#bib0095">19</a>Recommendation 2: In patients with RA it is recommended to start treatment with MTX preferably through an oral route. However, consideration should be given to sc or intramuscular routes in patients with poor compliance, insufficient effectiveness or gastrointestinal 14 side effects (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 91%).When Should the Clinician Change the Route of Administration?Change From Oral to SubcutaneousSome studies have suggested that patients with poor compliance, inadequate effectiveness and/or gastrointestinal side effects (when MTX was administered orally) should be considered when switching to injection<a class="elsevierStyleCrossRefs" href="#bib0100">20–23</a> because better results and effectiveness may be achieved. Changing to sc from oral in patients with a lack of response or toxicity has proven useful, with responses reaching 30% higher in the ACR20 criteria.<a class="elsevierStyleCrossRef" href="#bib0095">19</a> In addition, this change in patients with inadequate response could be cost-effective because it can prevent or delay therapy with biological agents.<a class="elsevierStyleCrossRefs" href="#bib0115">23–25</a>Recommendation 3: In patients with RA treated orally with MTX, available evidence justifies the change to sc route of administration when a lack of therapeutic response is expressed against the activity of the disease, or gastrointestinal toxicity or therapeutic failure are present, since the sc is associated with better treatment response<a class="elsevierStyleCrossRef" href="#bib0125">25</a> (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 100%).Recommendation 4: Its better cost-effectiveness in studies suggest the suitability of changing from oral administration to parenteral MTX in patients with an inadequate response, as the evidence shows that this prevents or delays subsequent therapy with biological agents<a class="elsevierStyleCrossRefs" href="#bib0115">23,25,26</a> (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 82%).Change From Subcutaneous Oral RouteThere are reasons for the change from SC to oral: sc administration intolerance, patient preferences, dose reduction to less than 7.5mg or therapeutic failure.Furthermore, it has been observed that if after switching to oral from sc, one desires to return to the sc route, the response rate may be lower compared to the first batch of parenteral MTX.<a class="elsevierStyleCrossRefs" href="#bib0095">19,21</a>Recommendation 5: Some clinical-care criteria can justify changing the route of administration from sc to oral MTX in RA patients: patient preferences, intolerance to the sc route of administration, dose reduction to levels <7.5mg/week, or low compliance<a class="elsevierStyleCrossRef" href="#bib0070">14</a> (LE: 4, [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D/√ [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 82%).How Should the Increase in Dose of Methotrexate be Made? Pattern and TimingSome studies show that initial doses of 25mg/week orally or rapid initial dose escalation therapeutic strategies of 5mg/month to 25–30mg/week are associated with greater efficiency; although with increased toxicity compared to the initial patterns of 5–15mg/week or slow escalation strategies of 5mg/3 months.<a class="elsevierStyleCrossRefs" href="#bib0060">12,27,28</a> These results support that achieving high doses (25–30mg/week) in a short period of time is effective, but may produce more adverse events.<a class="elsevierStyleCrossRef" href="#bib0065">13</a> It should also be noted that other studies with more aggressive strategies versus conventional increase patterns showed no statistically significant differences in therapeutic response.<a class="elsevierStyleCrossRefs" href="#bib0145">29,30</a>Moreover, in the dose range of 2.5–30mg/week of MTX, it is easy to reach the dose titration with small increments of 2.5mg offering even new formulations for parenteral administration. These are useful for problems of tolerance due to rapid dose escalation for lack of efficacy with the oral formulation.<a class="elsevierStyleCrossRefs" href="#bib0155">31,32</a>After evaluating this evidence, the panel of experts validated 2 recommendations:Recommendation 6: Once the initial dose of MTX has been established, if an adequate response in patients with RA is not achieved, proceed to a rapid increase of the dose up to 15–20 or even 25mg/week in about 8 weeks. Before making a dose increase, one should establish a clinical-therapeutic 4-week observation period, with the preceding dose to determine whether or not it is effective. In case of insufficient clinical response, increments of 2.5–5mg every 2–6 weeks are recommended, depending on the clinical severity, up to a maximum of 25mg weekly<a class="elsevierStyleCrossRef" href="#bib0120">24</a> (LE 5 [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165">33</a> DR: D [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165">33</a> A: 100%).If no response is seen after 8 weeks with a high dose of MTX, treatment should be discontinued, as indicated by the MTX insert.How Should the Clinician Reduce the Dose of Methotrexate? Pattern, Timing and Route of AdministrationDue to the paucity of evidence related to MTX dose reduction, the experts agreed to develop their own recommendations. The aim of downscaling is reaching the minimum effective dose to maintain a complete remission (DAS 28<2.6).Recommendation 7: Downscaling is recommended when complete remission is maintained for a period of time, depending on the dose:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005">•Dose ≥25mg/week: dose reduction will begin when there is sustained remission for at least 6 months.</li><li class="elsevierStyleListItem" id="lsti0010">•Doses <25mg/week: dose reduction will begin when there is sustained remission for at least 6–12 months (LE: 4 [SIGN] 9, DR: D/√[SIGN] 9, A: 91%).</li></ul>Recommendation 8: In patients with RA, as a general guideline for the downscaling of MTX, recommended reductions of 2.5–5mg every 3–6 months should be carried out (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D/√[SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 91%).As mentioned above, previous studies<a class="elsevierStyleCrossRef" href="#bib0095">19</a> show the consequences that could result from changes in route of administration. Therefore, it is agreed that:Recommendation 9: We recommend keeping track of the patient at the time of decision making (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D/√[SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 100%).However, doses below 15mg are candidates for oral treatment. Therefore, it is agreed:Recommendation 10: Arriving at doses of <15mg, it is considered appropriate to provide a change from sc to oral, except in the case of prior intolerance to oral or when there is suspected improvement in the efficiency related to the route of administration (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> DR: D/√[SIGN],<a class="elsevierStyleCrossRef" href="#bib0045">9</a> A: 91%).However, on downscaling during a change of parenteral to oral administration, it may be necessary to increase the oral dose to 2.5–5mg/week with respect to the parenteral dosage to maintain the effectiveness of the treatment.What Are the Recommendations for Evaluation and Monitoring for Patients With Rheumatoid Arthritis Receiving Methotrexate?Intensive monitoring of inflammatory activity and safety of treatment of RA in the early stages of its evolution is related to better results in remission and control of inflammatory disease activity.<a class="elsevierStyleCrossRefs" href="#bib0065">13,34,35</a> From the ACR<a class="elsevierStyleCrossRef" href="#bib0180">36</a> guidelines regarding the appropriate periodicity in the monitoring of these patients, Visser et al.<a class="elsevierStyleCrossRef" href="#bib0065">13</a> established parameters to review treatment as well as its periodicity, although for the latter there is less evidence.Recommendation 11: To initiate the process of increasing MTX dose, analytical control of ALT with/without AST, creatinine and CBC should be performed every month or month and a half until a stable dose is reached. From the clinical and therapeutic standpoint, monitoring is recommended every 1–3 months, with possible side effects and changes in risk factors monitored at each visit<a class="elsevierStyleCrossRef" href="#bib0065">13</a> (LE: 4 [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165">33</a> DR: C [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165">33</a> A: 91%).What Should Folic Acid Supplementation be in Patients With Rheumatoid Arthritis Treated With Methotrexate?MTX reduces inflammation by a mechanism related to folic acid metabolism. In some people treated with MTX there may be a deficiency in folic acid, so supplementation with folic acid or folinic may improve tolerability and safety of MTX (oral ulcers, gastrointestinal upset, diarrhea, hematological disorders, elevated transaminases). Folic or folinic acid is administered as one tablet of 5mg a week separating the drug at least one day with regard to the administration of MTX.<a class="elsevierStyleCrossRefs" href="#bib0185">37,38</a>Routine supplementation with folic/folinic acid generally does not affect the effectiveness of MTX, although the data of one study suggest that the use of these supplements could lead to a slight increase of the dose of MTX to maintain efficacy.<a class="elsevierStyleCrossRef" href="#bib0195">39</a>Recommendation 12: In patients with RA treated with MTX, administration of 5mg of folic or folinic acid/week is recommended, separating the intake of it from MTX by 24h<a class="elsevierStyleCrossRef" href="#bib0070">14</a> (LE: 1a/1b [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075">15</a> DR: A [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075">15</a> A: 100%).DiscussionThis consensus has been undertaken with the intent to facilitate decision making in the clinical practice of physicians involved in the management of patients with RA treated with MTX, the cornerstone of treatment of RA. Optimization is a process used to modify a system in order to increase its efficiency with the use of available resources. This has clearly been the goal of our consensus, trying to raise the profile of clinical use of this drug.Based on previous clinical questions, we have found evidence available on the initial dose of MTX used,<a class="elsevierStyleCrossRefs" href="#bib0050">10,19–26</a> the route of administration (and possible exchangeability)<a class="elsevierStyleCrossRefs" href="#bib0070">14,19</a>, therapeutic scaling,<a class="elsevierStyleCrossRefs" href="#bib0060">12,14,24,27,28,31,32,35</a> and optimal patient monitoring with MTX.<a class="elsevierStyleCrossRefs" href="#bib0065">13,36</a> Based on these reports, the panel of experts has made the appropriate recommendations, emphasizing issues such as who should start at full doses and quickly scale back to quickly gain control of the disease. We also emphasize the usefulness of the proper evaluation of the route of administration, at all times adapting to the characteristics of the individual and the clinical status of the disease.In conclusion, this paper gives some recommendations on the management of MTX in RA patients, and especially in the process of dose decreasing, which may facilitate clinical decision making and standardize the different ways to proceed.Ethical ResponsibilitiesProtection of people and animalsThe authors declare that this research did not perform experiments on humans or animals.Data confidentialityThe authors declare that they have followed the protocols of their workplace on the publication of data from patients and all patients included in the study have received sufficient information and gave written informed consent to participate in the study.Right to privacy and informed consentThe authors state that no patient data appears in this article.FundingThe study has been developed through an unrestricted grant offered by Gebro Pharma SA.Conflicts of InterestDr. Jesus Tornero Molina has received payments for research projects and conferences from Abbvie, Gebro, Pfizer and Roche.Dr. Jordi Carbonell states having an advisory contract with Gebro.The remaining authors declare that they have no conflict of interest related to the article." "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:2 [ "identificador" => "xres411386" "titulo" => array:5 [ 0 => "Abstract" 1 => "Objectives" 2 => "Materials and methods" 3 => "Results" 4 => "Conclusions" ] ] 1 => array:2 [ "identificador" => "xpalclavsec387024" "titulo" => "Keywords" ] 2 => array:2 [ "identificador" => "xres411385" "titulo" => array:5 [ 0 => "Resumen" 1 => "Objetivos" 2 => "Material y método" 3 => "Resultados" 4 => "Conclusiones" ] ] 3 => array:2 [ "identificador" => "xpalclavsec387025" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Materials and Methods" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Results" "secciones" => array:7 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "What Dose Methotrexate Should be Initiated in the Treatment of Rheumatoid Arthritis?" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "What Route of Administration Should Methotrexate be Initially Delivered Through?" ] 2 => array:3 [ "identificador" => "sec0030" "titulo" => "When Should the Clinician Change the Route of Administration?" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Change From Oral to Subcutaneous" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Change From Subcutaneous Oral Route" ] ] ] 3 => array:2 [ "identificador" => "sec0045" "titulo" => "How Should the Increase in Dose of Methotrexate be Made? Pattern and Timing" ] 4 => array:2 [ "identificador" => "sec0055" "titulo" => "How Should the Clinician Reduce the Dose of Methotrexate? Pattern, Timing and Route of Administration" ] 5 => array:2 [ "identificador" => "sec0060" "titulo" => "What Are the Recommendations for Evaluation and Monitoring for Patients With Rheumatoid Arthritis Receiving Methotrexate?" ] 6 => array:2 [ "identificador" => "sec0065" "titulo" => "What Should Folic Acid Supplementation be in Patients With Rheumatoid Arthritis Treated With Methotrexate?" ] ] ] 7 => array:2 [ "identificador" => "sec0070" "titulo" => "Discussion" ] 8 => array:3 [ "identificador" => "sec0075" "titulo" => "Ethical Responsibilities" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0080" "titulo" => "Protection of people and animals" ] 1 => array:2 [ "identificador" => "sec0085" "titulo" => "Data confidentiality" ] 2 => array:2 [ "identificador" => "sec0090" "titulo" => "Right to privacy and informed consent" ] ] ] 9 => array:2 [ "identificador" => "sec0095" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0100" "titulo" => "Conflicts of Interest" ] 11 => array:2 [ "identificador" => "xack121433" "titulo" => "Acknowledgments" ] 12 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2013-10-02" "fechaAceptado" => "2014-02-28" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec387024" "palabras" => array:4 [ 0 => "Methotrexate" 1 => "Rheumatoid arthritis" 2 => "Up and downscaling of the dose" 3 => "Consensus" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec387025" "palabras" => array:4 [ 0 => "Metotrexato" 1 => "Artritis reumatoide" 2 => "Incremento y reducción de dosis" 3 => "Consenso" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "ObjectivesTo describe the optimal therapeutic strategy for use of methotrexate in RA patients over the initial dose, route of administration, dose increase and decrease, patient monitoring, and use of folic/folinic acid. Materials and methodsEleven clinical experts proposed some questions to be solved. A systematic literature search was conducted. The contents were selected in a work session and subsequently validated via email to establish the level of agreement. ResultsThe initial dose of methotrexate should not be <10mg/week, preferably orally, but the parenteral route is considered as an alternative due to compliance, non-effectiveness of treatment or gastrointestinal side effects, polypharmacy, obesity (if required doses are >20mg/week), patient preference, very active disease or to avoid administration errors. Changing to a parenteral administration is proposed when the oral route is not effective enough, gastrointestinal toxicity appears, there is non-compliance or due to cost-effectiveness reasons before using more expensive drugs. On the contrary, due to patient preferences, intolerance to injections, dose reduction <7.5mg/week, non-effectiveness of the route, poor compliance or gastrointestinal side effects. There should be a rapid dose escalation if inadequate responses occur up to 15–20 or even 25mg/week in about 8 weeks, with increments of 2.5–5mg. The reduction will be carried out according to the dose the patient had, with decreases of 2.5–5mg every 3–6 months. Patient monitoring should be performed every 1–1.5 months until stability is reached and then for every 1–3 months. ConclusionsThis document pretends to solve some common clinical questions and facilitate decision-making in RA patients treated with methotrexate." ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "ObjetivosDescribir la estrategia terapéutica óptima de uso de metotrexato en AR sobre dosis inicial, vía de administración, incremento y disminución de dosis, seguimiento del paciente y uso de ácido fólico/folínico. Material y métodoOnce expertos plantearon los interrogantes clínicos a resolver. Se realizó una búsqueda bibliográfica sistemática. Los contenidos fueron seleccionados en una sesión de trabajo y el nivel de acuerdo se estableció posteriormente en una ronda de consenso vía correo. ResultadosLa dosis de inicio de metotrexato no debe ser < 10 mg/semana, preferentemente por vía oral, considerando la vía parenteral como alternativa según el cumplimento, ineficacia o efectos secundarios gastrointestinales, polimedicación, obesidad (si requiere dosis > 20 mg/semana), preferencias del paciente, enfermedad muy activa o para evitar errores de medicación. Se cambiará a la vía parenteral cuando haya ineficacia, toxicidad gastrointestinal, incumplimiento o por coste-efectividad antes de pasar a fármacos más caros; y a la inversa, según preferencias del paciente, intolerancia a inyectables, reducción de dosis < 7,5 mg/semana, ineficacia, bajo cumplimiento o efectos adversos gastrointestinales. Se realizará escalada rápida de dosis si la respuesta es inadecuada hasta los 15-20 o, incluso, 25 mg/semana en unas 8 semanas, con incrementos de 2,5-5 mg. La reducción se realizará según la dosis a la que estuviera el paciente, con disminuciones de 2,5-5 mg cada 3-6 meses. El seguimiento del paciente deberá realizarse cada 1-1,5 meses hasta la estabilidad y luego cada 1-3 meses. ConclusionesEste documento pretende resolver algunos interrogantes clínicos habituales y facilitar la toma de decisiones en la AR tratada con metotrexato." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Tornero Molina J, Ballina García FJ, Calvo Alén J, Caracuel Ruiz MÁ, Carbonell Abelló J, López Meseguer A, et al. Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración. Reumatol Clin. 2015;11:3–8." ] ] "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2094 "Ancho" => 2491 "Tamanyo" => 250662 ] ] "descripcion" => array:1 [ "en" => "Selection of citations made from the initial search to the writing of the article." ] ] 1 => array:7 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Block \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Matrix \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Screening \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Independent selection \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">1. Definitions and Interpretation. The efficacy and toxicity of DMARDs (hydroxychloroquine, and leflunomide) with MTX \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">84 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">2. Use of aspirin at antiplatelet doses in combination with MTX \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">3–5. Use of MTX when desiring pregnancy, during pregnancy and lactation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">166 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">6. Use of MTX in intercurrent infection, HCV, HBV, HIV, and tuberculosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">7. Use of MTX in minor and major surgery \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">123 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">8. MTX use in vaccination \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">9. Downscaling: in association with a biological, what should be reduced first? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">10. MTX dose fractioning \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="top">Total articles \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">475 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">37 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab639756.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Results of the Expanded Search for Specific Topics." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:39 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.R. Lard" 1 => "H. Visser" 2 => "I. Speyer" 3 => "I.E. vander Horst-Bruinsma" 4 => "A.H. Zwinderman" 5 => "F.C. Breedveld" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am J Med" "fecha" => "2001" "volumen" => "111" "paginaInicial" => "446" "paginaFinal" => "451" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11690569" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "V.P. Nell" 1 => "K.P. Machold" 2 => "G. Eberl" 3 => "T.A. Stamm" 4 => "M. Uffmann" 5 => "J.S. Smolen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2004" "volumen" => "43" "paginaInicial" => "906" "paginaFinal" => "914" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.A. Quinn" 1 => "P.G. Conaghan" 2 => "P. Emery" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2001" "volumen" => "40" "paginaInicial" => "1211" "paginaFinal" => "1220" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.S. Smolen" 1 => "R. Landewe" 2 => "F.C. Breedveld" 3 => "M. Dougados" 4 => "P. Emery" 5 => "C. Gaujoux-Viala" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.126532" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "964" "paginaFinal" => "975" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20444750" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Actualización de la guía de práctica clínica para el manejo de la artritis reumatoide en España. GuipCar 2007. Sociedad Española de Reumatología. Available from: <a href="http://www.ser.es/ArchivosDESCARGABLES/Proyectos/GUIPCAR_2007/GUIPCAR2007-Completa.pdf">http://www.ser.es/ArchivosDESCARGABLES/Proyectos/GUIPCAR_2007/GUIPCAR2007-Completa.pdf</a>" ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.G. Saag" 1 => "G.G. Teng" 2 => "N.M. Patkar" 3 => "J. Anuntiyo" 4 => "C. Finney" 5 => "J.R. Curtis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23721" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "59" "paginaInicial" => "762" "paginaFinal" => "784" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18512708" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of conventional disease-modifying anti-rheumatic drugs in established RA" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.S. Jurgens" 1 => "J.W. Jacobs" 2 => "J.W. Bijlsma" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.berh.2011.10.006" "Revista" => array:6 [ "tituloSerie" => "Best Pract Res Clin Rheumatol" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "523" "paginaFinal" => "533" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22137922" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elaboración de guías de práctica clínica en el Sistema Nacional de Salud. Manual Metodológico" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Grupo de trabajo sobre GPC" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2007" "editorial" => "Plan Nacional para el SNS del MSC, Instituto Aragonés de Ciencias de la Salud-I+CS Guías de Práctica Clínica en el SNS: I+CS no. 2006/0I" "editorialLocalizacion" => "Madrid" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SIGN 50: a guideline developers’ handbook" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Scottish Intercollegiate Guidelines Network" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2004" "editorial" => "SIGN" "editorialLocalizacion" => "Edinburgh" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.J. Williams" 1 => "R.F. Willkens" 2 => "C.O. Samuelson" 3 => "G.S. Alarcon" 4 => "M. Guttadauria" 5 => "C. Yarboro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1985" "volumen" => "28" "paginaInicial" => "721" "paginaFinal" => "730" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3893441" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of low-dose methotrexate in rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.E. Weinblatt" 1 => "J.S. Coblyn" 2 => "D.A. Fox" 3 => "P.A. Fraser" 4 => "D.E. Holdsworth" 5 => "D.N. Glass" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM198503283121303" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1985" "volumen" => "312" "paginaInicial" => "818" "paginaFinal" => "822" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3883172" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "D.E. Furst" 1 => "R. Koehnke" 2 => "L.F. Burmeister" 3 => "J. Kohler" 4 => "I. Cargill" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "1989" "volumen" => "16" "paginaInicial" => "313" "paginaFinal" => "320" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2724250" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Visser" 1 => "W. Katchamart" 2 => "E. Loza" 3 => "J.A. Martinez-Lopez" 4 => "C. Salliot" 5 => "J. Trudeau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2008.094474" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2009" "volumen" => "68" "paginaInicial" => "1086" "paginaFinal" => "1093" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19033291" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Pavy" 1 => "A. Constantin" 2 => "T. Pham" 3 => "L. Gossec" 4 => "J.F. Maillefert" 5 => "A. Cantagrel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jbspin.2006.01.007" "Revista" => array:6 [ "tituloSerie" => "Joint Bone Spine" "fecha" => "2006" "volumen" => "73" "paginaInicial" => "388" "paginaFinal" => "395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16626993" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical guidelines: developing guidelines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P.G. Shekelle" 1 => "S.H. Woolf" 2 => "M. Eccles" 3 => "J. Grimshaw" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "BMJ" "fecha" => "1999" "volumen" => "318" "paginaInicial" => "593" "paginaFinal" => "596" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10037645" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.W. Jundt" 1 => "B.A. Browne" 2 => "G.P. Fiocco" 3 => "A.D. Steele" 4 => "D. Mock" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "1993" "volumen" => "20" "paginaInicial" => "1845" "paginaFinal" => "1849" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8308768" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Hoekstra" 1 => "C. Haagsma" 2 => "C. Neef" 3 => "J. Proost" 4 => "A. Knuif" 5 => "M. van de Laar" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2004" "volumen" => "31" "paginaInicial" => "645" "paginaFinal" => "648" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15088287" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R.A. Hamilton" 1 => "J.M. Kremer" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Br J Rheumatol" "fecha" => "1997" "volumen" => "36" "paginaInicial" => "86" "paginaFinal" => "90" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9117183" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S095980490300368X" "estado" => "S300" "issn" => "09598049" ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase iv trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Braun" 1 => "P. Kastner" 2 => "P. Flaxenberg" 3 => "J. Wahrisch" 4 => "P. Hanke" 5 => "W. Demary" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.23144" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2008" "volumen" => "58" "paginaInicial" => "73" "paginaFinal" => "81" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18163521" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Wegrzyn" 1 => "P. Adeleine" 2 => "P. Miossec" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2003.011593" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2004" "volumen" => "63" "paginaInicial" => "1232" "paginaFinal" => "1234" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15361377" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Rozin" 1 => "D. Schapira" 2 => "A. Balbir-Gurman" 3 => "Y. Braun-Moscovici" 4 => "D. Markovits" 5 => "D. Militianu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2002" "volumen" => "61" "paginaInicial" => "756" "paginaFinal" => "757" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12117691" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Improving tolerance and bioavailability of methotrexate by switching from oral to subcutaneous route of administration" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Breslin" 1 => "C. Owen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2005" "volumen" => "44" "numero" => "Suppl. 1" "paginaInicial" => "i150" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Parenteral methotrexate should be given before biological therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S.J. Bingham" 1 => "M.H. Buch" 2 => "S. Lindsay" 3 => "A. Pollard" 4 => "J. White" 5 => "P. Emery" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2003" "volumen" => "42" "paginaInicial" => "1009" "paginaFinal" => "1010" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Actualización del Documento de consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide" ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.reuma.2009.10.006" "Revista" => array:6 [ "tituloSerie" => "Reumatol Clin" "fecha" => "2010" "volumen" => "6" "paginaInicial" => "23" "paginaFinal" => "36" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21794674" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "K. Alsufyani" 1 => "O. Ortiz-Alvarez" 2 => "D.A. Cabral" 3 => "L.B. Tucker" 4 => "R.E. Petty" 5 => "P.N. Malleson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Rheumatol" "fecha" => "2004" "volumen" => "31" "paginaInicial" => "179" "paginaFinal" => "182" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14705239" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Subcutaneous methotrexate is an effective alternative to biologic agents: results of a review of service provided" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K. Lindsay" 1 => "S. Shiela" 2 => "H. Lesley" 3 => "M. Sarah" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2006" "volumen" => "45" "numero" => "Suppl. 1" "paginaInicial" => "i124" ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tolerability of methotrexate starting with 15 or 25mg/week for rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Schnabel" 1 => "E. Reinhold-Keller" 2 => "V. Willmann" 3 => "W.L. Gross" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "1994" "volumen" => "14" "paginaInicial" => "33" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7939138" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.M. Verstappen" 1 => "J.W. Jacobs" 2 => "M.J. van der Veen" 3 => "A.H. Heurkens" 4 => "Y. Schenk" 5 => "E.J. Ter Borg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2007.071092" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2007" "volumen" => "66" "paginaInicial" => "1443" "paginaFinal" => "1449" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17519278" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methotrexate in rheumatoid arthritis, starting dose and dose escalation regimens" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "I.A.H. Jassim" 1 => "A. Al-Allaf" 2 => "P. Newton" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2007" "volumen" => "66" "paginaInicial" => "S440" "paginaFinal" => "S441" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C.M. Lambert" 1 => "S. Sandhu" 2 => "A. Lochhead" 3 => "N.P. Hurst" 4 => "E. McRorie" 5 => "V. Dhillon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.20167" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2004" "volumen" => "50" "paginaInicial" => "364" "paginaFinal" => "371" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14872477" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis. A post hoc analysis of the CAMERA study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.F. Bakker" 1 => "J.W.G. Jacobs" 2 => "P.M.J. Welsing" 3 => "J.H. van der Werf" 4 => "S.P. Linn-Rasker" 5 => "M.J. van der Veen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/ard.2009.124065" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2010" "volumen" => "69" "paginaInicial" => "1849" "paginaFinal" => "1852" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20511610" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.W. Jacobs" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rheumatology (Oxford)" "fecha" => "2012" "volumen" => "51" "numero" => "Suppl. 4" "paginaInicial" => "iv3" "paginaFinal" => "iv8" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Levels of evidence" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Oxford Centre for Evidence-Based Medicine" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2009" ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y.P.M. Goekoop-Ruiterman" 1 => "J.K. de Vries-Bouwstra" 2 => "C.F. Allaart" 3 => "D. van Zeben" 4 => "P.J.S.M. Kerstens" 5 => "J.M.W. Hazes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/art.21405" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2005" "volumen" => "52" "paginaInicial" => "3381" "paginaFinal" => "3390" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16258899" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Grigor" 1 => "H. Capell" 2 => "A. Stirling" 3 => "A.D. McMahon" 4 => "P. Lock" 5 => "R. Vallance" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(04)16676-2" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2004" "volumen" => "364" "paginaInicial" => "263" "paginaFinal" => "269" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15262104" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology ad hoc committee on clinical guidelines" ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "1996" "volumen" => "39" "paginaInicial" => "723" "paginaFinal" => "731" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8639168" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.S. Gao" 1 => "H. Wu" 2 => "J. Tian" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Zhonghua Er Ke Za Zhi" "fecha" => "2003" "volumen" => "41" "paginaInicial" => "435" "paginaFinal" => "438" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14748999" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "T. Niehues" 1 => "G. Horneff" 2 => "H. Michels" 3 => "M.S. Hock" 4 => "L. Schuchmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00296-004-0537-y" "Revista" => array:6 [ "tituloSerie" => "Rheumatol Int" "fecha" => "2005" "volumen" => "25" "paginaInicial" => "169" "paginaFinal" => "178" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15688190" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.E. Van Ede" 1 => "R.F. Laan" 2 => "M.J. Rood" 3 => "T.W. Huizinga" 4 => "M.A. van de Laar" 5 => "C.J. van Denderen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7" "Revista" => array:6 [ "tituloSerie" => "Arthritis Rheum" "fecha" => "2001" "volumen" => "44" "paginaInicial" => "1515" "paginaFinal" => "1524" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11465701" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack121433" "titulo" => "Acknowledgments" "texto" => "We thank Manel Alepuz and Veronica Albert, of Gestió Organització Comunicació, SA for their support in conducting the methodology used to prepare the study." "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001100000001/v1_201501160858/S2173574314000872/v1_201501160858/en/main.assets" "Apartado" => array:4 [ "identificador" => "5793" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Special article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001100000001/v1_201501160858/S2173574314000872/v1_201501160858/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314000872?idApp=UINPBA00004M"]

Statistics

Special Article

Recommendations for the Use of Methotrexate in Rheumatoid Arthritis: Up and Down Scaling of the Dose and Administration Routes

Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración

Jesús Tornero Molinaa,

Corresponding author

jtorneromolina@ser.es

Corresponding author.

, Francisco Javier Ballina Garcíab, Jaime Calvo Alénc, Miguel Ángel Caracuel Ruizd, Jordi Carbonell Abellóe, Antonio López Meseguerf, José Vicente Moreno Muelasg, Trinidad Pérez Sandovalh, Jesús Quijada Carrerai, Pilar Trenor Larrazj, Antonio Zea Mendozak

a Servicio de Reumatología, Hospital de Guadalajara, Guadalajara, Spain

b Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain

c Servicio de Reumatología, Hospital Universitario Sierrallana, Torrelavega, Cantabria, Spain

d Servicio de Reumatología, Hospital Reina Sofía, Córdoba, Spain

e Servicio de Reumatología, Hospital del Mar, Barcelona, Spain

f Servicio de Reumatología, Hospital Gutiérrez Ortega, Valdepeñas, Ciudad Real, Spain

g Servicio de Reumatología, Hospital Vall d’Hebron, Barcelona, Spain

h Servicio de Reumatología, Complejo Asistencia Universitario de León, León, Spain

i Servicio de Reumatología, Hospital Virgen del Rocío, Sevilla, Spain

j Servicio de Reumatología, Hospital Clínico Universitario de Valencia, Valencia, Spain

k Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, Spain

Read

39543

Times
was read the article

4489

Total PDF

35054

Total HTML

Share statistics

 array:23 [
  "pii" => "S2173574314000872"
  "issn" => "21735743"
  "doi" => "10.1016/j.reumae.2014.02.006"
  "estado" => "S300"
  "fechaPublicacion" => "2015-01-01"
  "aid" => "667"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;. All rights reserved"
  "copyrightAnyo" => "2013"
  "documento" => "article"
  "subdocumento" => "fla"
  "cita" => "Reumatol Clin. 2015;11:3-8"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 3501
    "formatos" => array:3 [
      "EPUB" => 60
      "HTML" => 2861
      "PDF" => 580
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:18 [
      "pii" => "S1699258X1400059X"
      "issn" => "1699258X"
      "doi" => "10.1016/j.reuma.2014.02.012"
      "estado" => "S300"
      "fechaPublicacion" => "2015-01-01"
      "aid" => "667"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
      "documento" => "article"
      "subdocumento" => "fla"
      "cita" => "Reumatol Clin. 2015;11:3-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 34156
        "formatos" => array:3 [
          "EPUB" => 206
          "HTML" => 29372
          "PDF" => 4578
        ]
      ]
      "es" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Art&#237;culo especial</span>"
        "titulo" => "Recomendaciones para el uso del metotrexato en artritis reumatoide&#58; incremento y reducci&#243;n de dosis y v&#237;as de administraci&#243;n"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "3"
            "paginaFinal" => "8"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Recommendations for the use of methotrexate in rheumatoid arthritis&#58; Up and down scaling of the dose and administration routes"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 2094
                "Ancho" => 2490
                "Tamanyo" => 255921
              ]
            ]
            "descripcion" => array:1 [
              "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Selecci&#243;n de citas bibliogr&#225;ficas realizada desde la b&#250;squeda inicial hasta la redacci&#243;n del art&#237;culo&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Jes&#250;s Tornero Molina, Francisco Javier Ballina Garc&#237;a, Jaime Calvo Al&#233;n, Miguel &#193;ngel Caracuel Ruiz, Jordi Carbonell Abell&#243;, Antonio L&#243;pez Meseguer, Jos&#233; Vicente Moreno Muelas, Trinidad P&#233;rez Sandoval, Jes&#250;s Quijada Carrera, Pilar Trenor Larraz, Antonio Zea Mendoza"
            "autores" => array:11 [
              0 => array:2 [
                "nombre" => "Jes&#250;s"
                "apellidos" => "Tornero Molina"
              ]
              1 => array:2 [
                "nombre" => "Francisco Javier"
                "apellidos" => "Ballina Garc&#237;a"
              ]
              2 => array:2 [
                "nombre" => "Jaime"
                "apellidos" => "Calvo Al&#233;n"
              ]
              3 => array:2 [
                "nombre" => "Miguel &#193;ngel"
                "apellidos" => "Caracuel Ruiz"
              ]
              4 => array:2 [
                "nombre" => "Jordi"
                "apellidos" => "Carbonell Abell&#243;"
              ]
              5 => array:2 [
                "nombre" => "Antonio"
                "apellidos" => "L&#243;pez Meseguer"
              ]
              6 => array:2 [
                "nombre" => "Jos&#233; Vicente"
                "apellidos" => "Moreno Muelas"
              ]
              7 => array:2 [
                "nombre" => "Trinidad"
                "apellidos" => "P&#233;rez Sandoval"
              ]
              8 => array:2 [
                "nombre" => "Jes&#250;s"
                "apellidos" => "Quijada Carrera"
              ]
              9 => array:2 [
                "nombre" => "Pilar"
                "apellidos" => "Trenor Larraz"
              ]
              10 => array:2 [
                "nombre" => "Antonio"
                "apellidos" => "Zea Mendoza"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2173574314000872"
          "doi" => "10.1016/j.reumae.2014.02.006"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314000872?idApp=UINPBA00004M"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X1400059X?idApp=UINPBA00004M"
      "url" => "/1699258X/0000001100000001/v2_201706020231/S1699258X1400059X/v2_201706020231/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2173574314001129"
    "issn" => "21735743"
    "doi" => "10.1016/j.reumae.2014.03.020"
    "estado" => "S300"
    "fechaPublicacion" => "2015-01-01"
    "aid" => "672"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "simple-article"
    "subdocumento" => "crp"
    "cita" => "Reumatol Clin. 2015;11:9-11"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 2574
      "formatos" => array:3 [
        "EPUB" => 64
        "HTML" => 2190
        "PDF" => 320
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Brief report</span>"
      "titulo" => "Is It Safe to Perform Joint Infiltrations or Aspirations in Patients Anticoagulated With Acenocoumarol?"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "9"
          "paginaFinal" => "11"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "¿Es seguro realizar infiltraciones o aspiraciones articulares en pacientes anticoagulados con acenocumarol?"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Carlos Guillen Astete, Alina Boteanu, Carmen Medina Quiñones, Nuria Garcia Montes, Fernando Roldan Moll, César Carballo Carmano, Antonio Zea Mendoza"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Guillen Astete"
            ]
            1 => array:2 [
              "nombre" => "Alina"
              "apellidos" => "Boteanu"
            ]
            2 => array:2 [
              "nombre" => "Carmen"
              "apellidos" => "Medina Quiñones"
            ]
            3 => array:2 [
              "nombre" => "Nuria"
              "apellidos" => "Garcia Montes"
            ]
            4 => array:2 [
              "nombre" => "Fernando"
              "apellidos" => "Roldan Moll"
            ]
            5 => array:2 [
              "nombre" => "César"
              "apellidos" => "Carballo Carmano"
            ]
            6 => array:2 [
              "nombre" => "Antonio"
              "apellidos" => "Zea Mendoza"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S1699258X14000801"
        "doi" => "10.1016/j.reuma.2014.03.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X14000801?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314001129?idApp=UINPBA00004M"
    "url" => "/21735743/0000001100000001/v1_201501160858/S2173574314001129/v1_201501160858/en/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2173574315000040"
    "issn" => "21735743"
    "doi" => "10.1016/j.reumae.2014.09.004"
    "estado" => "S300"
    "fechaPublicacion" => "2015-01-01"
    "aid" => "720"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46;"
    "documento" => "article"
    "subdocumento" => "sco"
    "cita" => "Reumatol Clin. 2015;11:1-2"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 1521
      "formatos" => array:3 [
        "EPUB" => 59
        "HTML" => 1193
        "PDF" => 269
      ]
    ]
    "en" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Autoimmune flares. The hows, whens, and whys of killing"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "1"
          "paginaFinal" => "2"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Cómo, cuando y por qué matar durante los brotes en las enfermedades autoinmunes"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Olga Sánchez-Pernaute"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Olga"
              "apellidos" => "Sánchez-Pernaute"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1699258X1400206X"
        "doi" => "10.1016/j.reuma.2014.09.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X1400206X?idApp=UINPBA00004M"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574315000040?idApp=UINPBA00004M"
    "url" => "/21735743/0000001100000001/v1_201501160858/S2173574315000040/v1_201501160858/en/main.assets"
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>"
    "titulo" => "Recommendations for the Use of Methotrexate in Rheumatoid Arthritis: Up and Down Scaling of the Dose and Administration Routes"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "3"
        "paginaFinal" => "8"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Jesús Tornero Molina, Francisco Javier Ballina García, Jaime Calvo Alén, Miguel Ángel Caracuel Ruiz, Jordi Carbonell Abelló, Antonio López Meseguer, José Vicente Moreno Muelas, Trinidad Pérez Sandoval, Jesús Quijada Carrera, Pilar Trenor Larraz, Antonio Zea Mendoza"
        "autores" => array:11 [
          0 => array:4 [
            "nombre" => "Jesús"
            "apellidos" => "Tornero Molina"
            "email" => array:1 [
              0 => "jtorneromolina@ser.es"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Francisco Javier"
            "apellidos" => "Ballina García"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Jaime"
            "apellidos" => "Calvo Alén"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Miguel Ángel"
            "apellidos" => "Caracuel Ruiz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Jordi"
            "apellidos" => "Carbonell Abelló"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Antonio"
            "apellidos" => "López Meseguer"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "José Vicente"
            "apellidos" => "Moreno Muelas"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Trinidad"
            "apellidos" => "Pérez Sandoval"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Jesús"
            "apellidos" => "Quijada Carrera"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Pilar"
            "apellidos" => "Trenor Larraz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">j</span>"
                "identificador" => "aff0050"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Antonio"
            "apellidos" => "Zea Mendoza"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">k</span>"
                "identificador" => "aff0055"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:11 [
          0 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital de Guadalajara, Guadalajara, Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Universitario Central de Asturias, Oviedo, Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Universitario Sierrallana, Torrelavega, Cantabria, Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Reina Sofía, Córdoba, Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital del Mar, Barcelona, Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Gutiérrez Ortega, Valdepeñas, Ciudad Real, Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Vall d&#8217;Hebron, Barcelona, Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Reumatología, Complejo Asistencia Universitario de León, León, Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Virgen del Rocío, Sevilla, Spain"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
          9 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Clínico Universitario de Valencia, Valencia, Spain"
            "etiqueta" => "j"
            "identificador" => "aff0050"
          ]
          10 => array:3 [
            "entidad" => "Servicio de Reumatología, Hospital Universitario Ramón y Cajal, Madrid, Spain"
            "etiqueta" => "k"
            "identificador" => "aff0055"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author."
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2094
            "Ancho" => 2491
            "Tamanyo" => 250662
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Selection of citations made from the initial search to the writing of the article.</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The correct use of disease-modifying antirheumatic drugs (DMARDs) has improved the prognosis of RA based on its early use and setting a specific therapeutic goal, aiming to reach remission or the lowest possible degrees of inflammatory activity.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1&#8211;3</span></a> In this sense, EULAR recommends that DMARD treatment should begin as soon as the diagnosis of RA is made.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Methotrexate (MTX) has been used for over 20 years in the treatment of rheumatoid arthritis. The features that make the MTX as the DMARD of first choice are related to its low price, its favorable safety profile, its slowing of radiographic progression, clinical experience with high response rates, therapeutic continuity, availability and versatility of doses and routes of administration. Thus, after the diagnosis of the disease, it is indicated as the first-line treatment for early and in clearly defined RA, as recommended by different societies<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4&#8211;6</span></a>, and it is also suitable as an anchor drug for combination therapies.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">However, there is a large variability in the clinical practice in our country with regard to the starting dose, the rate and pattern of dose escalation, selection of routes of administration and dosing with concomitant use of folic acid or folinic acid in patients with RA. This is because the clinical practice may not be clearly supported by appropriate clinical trials.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The objective of this study is to establish recommendations for decision-making in the treatment of adult RA with MTX, based on scientific evidence.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and Methods</span><p id="par0025" class="elsevierStylePara elsevierViewall">For the preparation of the consensus document a group of experts, who drafted the recommendations (ER), was made up by 11 rheumatologists from hospitals of the Spanish National Health System. The ER worked according to the methodological basis given by the Quality Plan of the Ministry of Health, in its reference document &#8220;Development of clinical practice guidelines in the National Health System&#8221;.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">The ER work in the context of the use of MTX in the treatment of adult RA was performed with a participatory and structured methodology, in which ER members identified 3 major blocks: (a) indication criteria; (b) initial dose and route of administration and changes along the treatment; (c) criteria for dose modification and withdrawal of MTX. A detailed index was established to solve clinical questions, to which they later applied the PICO methodology, in order to facilitate and manage the process of literature search and the subsequent development of specific recommendations developed in response to each issue raised. The systematic review of the literature was used as the basic source of the original query, clinical trials, cohort studies, protocols, review articles and clinical guidelines. Filter criteria and the search limits were established by the ER panel. The objective of all of this was to make feasible an updated and critical reading of the key aspects of the scientific evidence available. A search for articles published since 1995 was conducted, both in English and Spanish, in databases such as PubMed, Cochrane Bookseller, Trip data base and abstracts of the congresses of the Spanish Society of Rheumatology (2005&#8211;2012), <span class="elsevierStyleItalic">The European League Against Rheumatism</span> (2012) and the <span class="elsevierStyleItalic">American College of Rheumatology</span> (2010&#8211;2011) and in the latest update available for MTX data sheets for both oral and parenteral formulations (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">The initial search result yielded 1241 articles. Relevant articles were selected in 2 phases. The first prioritized titles and abstracts (177), and the second prioritized consensus statements, specific systematic reviews and most recent articles (46). The ER panel considered necessary, in very specific cases, a complementary search in certain areas of therapeutic care, which were not sufficiently defined in the initial search strategy (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Because of the predominance of review articles and clinical guidelines, references to the summary report of the literature were expanded to a total of 182 citations.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">The categorization of levels of evidence (LE) and degrees of recommendation (DR) was performed from system criteria <span class="elsevierStyleItalic">Scottish Intercollegiate Guidelines Network</span> (SIGN)<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> themes that used diagnostic criteria of the &#8220;Center-based medicine evidence of Oxford &#8220;(CMBE). For recommendations that already had NE and/or in other previous documents DR originals are kept, referencing it in each case.</p><p id="par0045" class="elsevierStylePara elsevierViewall">The executive summary of the evidence was assessed in a participatory classroom session, in which 37 recommendations and 14 were proposed evidence. This document was sent to the ER members for their individual assessment and to vote on their agreement, to regard these recommendations as appropriate responses to the clinical questions posed. Finally, 12 recommendations reached an agreement (A) greater than 70% were established as validated formal recommendations.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Results</span><p id="par0050" class="elsevierStylePara elsevierViewall">From the literature search and the articles referred, prioritized by the ER members specifically, this document regarding answers to clinical questions raised was developed, with the objective to reduce the variability in the use of MTX in the treatment of adult RA. The 12 recommendations that reached greater agreement among members of the ER panel are here presented. Of these, 10 have their scientific basis in 28 of the references cited, while 2 correspond to recommendations based from experience and expert opinion of the ER panel.</p><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">What Dose Methotrexate Should be Initiated in the Treatment of Rheumatoid Arthritis?</span><p id="par0055" class="elsevierStylePara elsevierViewall">It is known that the effectiveness of MTX is dose dependent. Results of some studies indicate that an initial dose of 7.5<span class="elsevierStyleHsp" style=""></span>mg/week was often ineffective and, in many cases required an increase in dose after 6 weeks.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,11</span></a> In addition, a starting dose of 12.5&#8211;20<span class="elsevierStyleHsp" style=""></span>mg/week was more effective than 5&#8211;7.5<span class="elsevierStyleHsp" style=""></span>mg/week, with no differences in safety.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Therefore, some experts recommend a minimum initial dose of at least 10<span class="elsevierStyleHsp" style=""></span>mg/week, although it is more complicated to establish agreement on what to recommend as an optimal initial dose. However, a systematic review<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> defends the optimal initial dose of 10&#8211;15<span class="elsevierStyleHsp" style=""></span>mg<span class="elsevierStyleMonospace">/</span>week orally, taking into account the specific characteristics of each patient. Based on these evidences, a dose not lower than 10<span class="elsevierStyleHsp" style=""></span>mg/week is recommended; but also lower doses may be considered depending on the circumstances of the patient (comorbidities, low weight, age, renal function, liver).</p><p id="par0060" class="elsevierStylePara elsevierViewall">Recommendation 1: For RA, a starting dose of MTX not less than 10<span class="elsevierStyleHsp" style=""></span>mg/week should be determined, based on the severity of the disease and prognostic factors associated with the patient<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> (LE: 1b/2 [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> DR: C [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> A: 82%).</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">What Route of Administration Should Methotrexate be Initially Delivered Through?</span><p id="par0065" class="elsevierStylePara elsevierViewall">The selection of the initial route of administration may be agreed upon between the doctor and the patient. Generally, the patient usually prefers the oral route. Different studies show that the relative bioavailability of oral MTX compared to the intramuscular MTX is good at low doses but decreases at higher doses (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16&#8211;18</span></a> Considering that the relationship between oral bioavailability and parenteral dosage is 1 for total doses of 7.5<span class="elsevierStyleHsp" style=""></span>mg, it becomes 0.85 (range 0.77&#8211;0.93) when the total dosage reaches 10&#8211;15<span class="elsevierStyleHsp" style=""></span>mg and drops to 0.64 (range 0.21&#8211;0.94) at doses of 15&#8211;20<span class="elsevierStyleHsp" style=""></span>mg.Therefore, a dosage under 20<span class="elsevierStyleHsp" style=""></span>mg/week, ease of handling and low cost of oral MTX position it as the preferred route of administration in RA<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a>; however, after 15<span class="elsevierStyleHsp" style=""></span>mg/week there is no evidence that the oral route is better than parenteral.</p><p id="par0070" class="elsevierStylePara elsevierViewall">However, there are situations in which to consider the parenteral route as the route of choice from the start: polypharmacy patients who are overweight or obese (as administered doses are higher), low compliance, per patient preference in order to reduce certain gastrointestinal adverse effects or to avoid medication errors. In addition, experimental data seem to indicate that the subcutaneous (sc) onset is especially useful in patients with active, longstanding disease (DAS 28&#8805;4).<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Recommendation 2: In patients with RA it is recommended to start treatment with MTX preferably through an oral route. However, consideration should be given to sc or intramuscular routes in patients with poor compliance, insufficient effectiveness or gastrointestinal 14 side effects (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 91%).</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">When Should the Clinician Change the Route of Administration?</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Change From Oral to Subcutaneous</span><p id="par0080" class="elsevierStylePara elsevierViewall">Some studies have suggested that patients with poor compliance, inadequate effectiveness and/or gastrointestinal side effects (when MTX was administered orally) should be considered when switching to injection<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#8211;23</span></a> because better results and effectiveness may be achieved. Changing to sc from oral in patients with a lack of response or toxicity has proven useful, with responses reaching 30% higher in the ACR20 criteria.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> In addition, this change in patients with inadequate response could be cost-effective because it can prevent or delay therapy with biological agents.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23&#8211;25</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Recommendation 3: In patients with RA treated orally with MTX, available evidence justifies the change to sc route of administration when a lack of therapeutic response is expressed against the activity of the disease, or gastrointestinal toxicity or therapeutic failure are present, since the sc is associated with better treatment response<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 100%).</p><p id="par0090" class="elsevierStylePara elsevierViewall">Recommendation 4: Its better cost-effectiveness in studies suggest the suitability of changing from oral administration to parenteral MTX in patients with an inadequate response, as the evidence shows that this prevents or delays subsequent therapy with biological agents<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23,25,26</span></a> (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 82%).</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Change From Subcutaneous Oral Route</span><p id="par0095" class="elsevierStylePara elsevierViewall">There are reasons for the change from SC to oral: sc administration intolerance, patient preferences, dose reduction to less than 7.5<span class="elsevierStyleHsp" style=""></span>mg or therapeutic failure.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Furthermore, it has been observed that if after switching to oral from sc, one desires to return to the sc route, the response rate may be lower compared to the first batch of parenteral MTX.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,21</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Recommendation 5: Some clinical-care criteria can justify changing the route of administration from sc to oral MTX in RA patients: patient preferences, intolerance to the sc route of administration, dose reduction to levels &#60;7.5<span class="elsevierStyleHsp" style=""></span>mg/week, or low compliance<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> (LE: 4, [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D/&#8730; [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 82%).</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">How Should the Increase in Dose of Methotrexate be Made? Pattern and Timing</span><p id="par0110" class="elsevierStylePara elsevierViewall">Some studies show that initial doses of 25<span class="elsevierStyleHsp" style=""></span>mg/week orally or rapid initial dose escalation therapeutic strategies of 5<span class="elsevierStyleHsp" style=""></span>mg/month to 25&#8211;30<span class="elsevierStyleHsp" style=""></span>mg/week are associated with greater efficiency; although with increased toxicity compared to the initial patterns of 5&#8211;15<span class="elsevierStyleHsp" style=""></span>mg/week or slow escalation strategies of 5<span class="elsevierStyleHsp" style=""></span>mg/3 months.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,27,28</span></a> These results support that achieving high doses (25&#8211;30<span class="elsevierStyleHsp" style=""></span>mg/week) in a short period of time is effective, but may produce more adverse events.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> It should also be noted that other studies with more aggressive strategies versus conventional increase patterns showed no statistically significant differences in therapeutic response.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">29,30</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">Moreover, in the dose range of 2.5&#8211;30<span class="elsevierStyleHsp" style=""></span>mg/week of MTX, it is easy to reach the dose titration with small increments of 2.5<span class="elsevierStyleHsp" style=""></span>mg offering even new formulations for parenteral administration. These are useful for problems of tolerance due to rapid dose escalation for lack of efficacy with the oral formulation.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">31,32</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">After evaluating this evidence, the panel of experts validated 2 recommendations:</p><p id="par0260" class="elsevierStylePara elsevierViewall">Recommendation 6: Once the initial dose of MTX has been established, if an adequate response in patients with RA is not achieved, proceed to a rapid increase of the dose up to 15&#8211;20 or even 25<span class="elsevierStyleHsp" style=""></span>mg/week in about 8 weeks. Before making a dose increase, one should establish a clinical-therapeutic 4-week observation period, with the preceding dose to determine whether or not it is effective. In case of insufficient clinical response, increments of 2.5&#8211;5<span class="elsevierStyleHsp" style=""></span>mg every 2&#8211;6 weeks are recommended, depending on the clinical severity, up to a maximum of 25<span class="elsevierStyleHsp" style=""></span>mg weekly<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> (LE 5 [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> DR: D [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> A: 100%).</p><p id="par0125" class="elsevierStylePara elsevierViewall">If no response is seen after 8 weeks with a high dose of MTX, treatment should be discontinued, as indicated by the MTX insert.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">How Should the Clinician Reduce the Dose of Methotrexate? Pattern, Timing and Route of Administration</span><p id="par0130" class="elsevierStylePara elsevierViewall">Due to the paucity of evidence related to MTX dose reduction, the experts agreed to develop their own recommendations. The aim of downscaling is reaching the minimum effective dose to maintain a complete remission (DAS 28<span class="elsevierStyleMonospace">&#60;</span>2.6).</p><p id="par0135" class="elsevierStylePara elsevierViewall">Recommendation 7: Downscaling is recommended when complete remission is maintained for a period of time, depending on the dose:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">&#8226;</span><p id="par0140" class="elsevierStylePara elsevierViewall">Dose &#8805;25<span class="elsevierStyleHsp" style=""></span>mg/week: dose reduction will begin when there is sustained remission for at least 6 months.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">&#8226;</span><p id="par0145" class="elsevierStylePara elsevierViewall">Doses &#60;25<span class="elsevierStyleHsp" style=""></span>mg/week: dose reduction will begin when there is sustained remission for at least 6&#8211;12 months (LE: 4 [SIGN] 9, DR: D/&#8730;[SIGN] 9, A: 91%).</p></li></ul></p><p id="par0150" class="elsevierStylePara elsevierViewall">Recommendation 8: In patients with RA, as a general guideline for the downscaling of MTX, recommended reductions of 2.5&#8211;5<span class="elsevierStyleHsp" style=""></span>mg every 3&#8211;6 months should be carried out (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D/&#8730;[SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 91%).</p><p id="par0155" class="elsevierStylePara elsevierViewall">As mentioned above, previous studies<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> show the consequences that could result from changes in route of administration. Therefore, it is agreed that:</p><p id="par0160" class="elsevierStylePara elsevierViewall">Recommendation 9: We recommend keeping track of the patient at the time of decision making (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D/&#8730;[SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 100%).</p><p id="par0165" class="elsevierStylePara elsevierViewall">However, doses below 15<span class="elsevierStyleHsp" style=""></span>mg are candidates for oral treatment. Therefore, it is agreed:</p><p id="par0170" class="elsevierStylePara elsevierViewall">Recommendation 10: Arriving at doses of &#60;15<span class="elsevierStyleHsp" style=""></span>mg, it is considered appropriate to provide a change from sc to oral, except in the case of prior intolerance to oral or when there is suspected improvement in the efficiency related to the route of administration (LE: 4 [SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> DR: D/&#8730;[SIGN],<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> A: 91%).</p><p id="par0175" class="elsevierStylePara elsevierViewall">However, on downscaling during a change of parenteral to oral administration, it may be necessary to increase the oral dose to 2.5&#8211;5<span class="elsevierStyleHsp" style=""></span>mg/week with respect to the parenteral dosage to maintain the effectiveness of the treatment.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">What Are the Recommendations for Evaluation and Monitoring for Patients With Rheumatoid Arthritis Receiving Methotrexate?</span><p id="par0180" class="elsevierStylePara elsevierViewall">Intensive monitoring of inflammatory activity and safety of treatment of RA in the early stages of its evolution is related to better results in remission and control of inflammatory disease activity.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,34,35</span></a> From the ACR<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">36</span></a> guidelines regarding the appropriate periodicity in the monitoring of these patients, Visser et al.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> established parameters to review treatment as well as its periodicity, although for the latter there is less evidence.</p><p id="par0185" class="elsevierStylePara elsevierViewall">Recommendation 11: To initiate the process of increasing MTX dose, analytical control of ALT with/without AST, creatinine and CBC should be performed every month or month and a half until a stable dose is reached. From the clinical and therapeutic standpoint, monitoring is recommended every 1&#8211;3 months, with possible side effects and changes in risk factors monitored at each visit<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">13</span></a> (LE: 4 [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> DR: C [Oxford],<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> A: 91%).</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">What Should Folic Acid Supplementation be in Patients With Rheumatoid Arthritis Treated With Methotrexate?</span><p id="par0190" class="elsevierStylePara elsevierViewall">MTX reduces inflammation by a mechanism related to folic acid metabolism. In some people treated with MTX there may be a deficiency in folic acid, so supplementation with folic acid or folinic may improve tolerability and safety of MTX (oral ulcers, gastrointestinal upset, diarrhea, hematological disorders, elevated transaminases). Folic or folinic acid is administered as one tablet of 5<span class="elsevierStyleHsp" style=""></span>mg a week separating the drug at least one day with regard to the administration of MTX.<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">37,38</span></a></p><p id="par0195" class="elsevierStylePara elsevierViewall">Routine supplementation with folic/folinic acid generally does not affect the effectiveness of MTX, although the data of one study suggest that the use of these supplements could lead to a slight increase of the dose of MTX to maintain efficacy.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">Recommendation 12: In patients with RA treated with MTX, administration of 5<span class="elsevierStyleHsp" style=""></span>mg of folic or folinic acid<span class="elsevierStyleMonospace">/</span>week is recommended, separating the intake of it from MTX by 24<span class="elsevierStyleHsp" style=""></span>h<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> (LE: 1a/1b [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> DR: A [Shekelle],<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> A: 100%).</p></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Discussion</span><p id="par0205" class="elsevierStylePara elsevierViewall">This consensus has been undertaken with the intent to facilitate decision making in the clinical practice of physicians involved in the management of patients with RA treated with MTX, the cornerstone of treatment of RA. Optimization is a process used to modify a system in order to increase its efficiency with the use of available resources. This has clearly been the goal of our consensus, trying to raise the profile of clinical use of this drug.</p><p id="par0210" class="elsevierStylePara elsevierViewall">Based on previous clinical questions, we have found evidence available on the initial dose of MTX used,<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,19&#8211;26</span></a> the route of administration (and possible exchangeability)<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,19</span></a>, therapeutic scaling,<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,14,24,27,28,31,32,35</span></a> and optimal patient monitoring with MTX.<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13,36</span></a> Based on these reports, the panel of experts has made the appropriate recommendations, emphasizing issues such as who should start at full doses and quickly scale back to quickly gain control of the disease. We also emphasize the usefulness of the proper evaluation of the route of administration, at all times adapting to the characteristics of the individual and the clinical status of the disease.</p><p id="par0215" class="elsevierStylePara elsevierViewall">In conclusion, this paper gives some recommendations on the management of MTX in RA patients, and especially in the process of dose decreasing, which may facilitate clinical decision making and standardize the different ways to proceed.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Ethical Responsibilities</span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Protection of people and animals</span><p id="par0220" class="elsevierStylePara elsevierViewall">The authors declare that this research did not perform experiments on humans or animals.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Data confidentiality</span><p id="par0225" class="elsevierStylePara elsevierViewall">The authors declare that they have followed the protocols of their workplace on the publication of data from patients and all patients included in the study have received sufficient information and gave written informed consent to participate in the study.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Right to privacy and informed consent</span><p id="par0230" class="elsevierStylePara elsevierViewall">The authors state that no patient data appears in this article.</p></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Funding</span><p id="par0235" class="elsevierStylePara elsevierViewall">The study has been developed through an unrestricted grant offered by <span class="elsevierStyleGrantSponsor" id="gs0005">Gebro Pharma SA</span>.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Conflicts of Interest</span><p id="par0240" class="elsevierStylePara elsevierViewall">Dr. Jesus Tornero Molina has received payments for research projects and conferences from Abbvie, Gebro, Pfizer and Roche.</p><p id="par0245" class="elsevierStylePara elsevierViewall">Dr. Jordi Carbonell states having an advisory contract with Gebro.</p><p id="par0250" class="elsevierStylePara elsevierViewall">The remaining authors declare that they have no conflict of interest related to the article.</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:13 [
        0 => array:2 [
          "identificador" => "xres411386"
          "titulo" => array:5 [
            0 => "Abstract"
            1 => "Objectives"
            2 => "Materials and methods"
            3 => "Results"
            4 => "Conclusions"
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec387024"
          "titulo" => "Keywords"
        ]
        2 => array:2 [
          "identificador" => "xres411385"
          "titulo" => array:5 [
            0 => "Resumen"
            1 => "Objetivos"
            2 => "Material y m&eacute;todo"
            3 => "Resultados"
            4 => "Conclusiones"
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec387025"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Materials and Methods"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Results"
          "secciones" => array:7 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "What Dose Methotrexate Should be Initiated in the Treatment of Rheumatoid Arthritis?"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "What Route of Administration Should Methotrexate be Initially Delivered Through?"
            ]
            2 => array:3 [
              "identificador" => "sec0030"
              "titulo" => "When Should the Clinician Change the Route of Administration?"
              "secciones" => array:2 [
                0 => array:2 [
                  "identificador" => "sec0035"
                  "titulo" => "Change From Oral to Subcutaneous"
                ]
                1 => array:2 [
                  "identificador" => "sec0040"
                  "titulo" => "Change From Subcutaneous Oral Route"
                ]
              ]
            ]
            3 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "How Should the Increase in Dose of Methotrexate be Made? Pattern and Timing"
            ]
            4 => array:2 [
              "identificador" => "sec0055"
              "titulo" => "How Should the Clinician Reduce the Dose of Methotrexate? Pattern, Timing and Route of Administration"
            ]
            5 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "What Are the Recommendations for Evaluation and Monitoring for Patients With Rheumatoid Arthritis Receiving Methotrexate?"
            ]
            6 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "What Should Folic Acid Supplementation be in Patients With Rheumatoid Arthritis Treated With Methotrexate?"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Discussion"
        ]
        8 => array:3 [
          "identificador" => "sec0075"
          "titulo" => "Ethical Responsibilities"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0080"
              "titulo" => "Protection of people and animals"
            ]
            1 => array:2 [
              "identificador" => "sec0085"
              "titulo" => "Data confidentiality"
            ]
            2 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Right to privacy and informed consent"
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0095"
          "titulo" => "Funding"
        ]
        10 => array:2 [
          "identificador" => "sec0100"
          "titulo" => "Conflicts of Interest"
        ]
        11 => array:2 [
          "identificador" => "xack121433"
          "titulo" => "Acknowledgments"
        ]
        12 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2013-10-02"
    "fechaAceptado" => "2014-02-28"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec387024"
          "palabras" => array:4 [
            0 => "Methotrexate"
            1 => "Rheumatoid arthritis"
            2 => "Up and downscaling of the dose"
            3 => "Consensus"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec387025"
          "palabras" => array:4 [
            0 => "Metotrexato"
            1 => "Artritis reumatoide"
            2 => "Incremento y reducción de dosis"
            3 => "Consenso"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0010">Objectives</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To describe the optimal therapeutic strategy for use of methotrexate in RA patients over the initial dose, route of administration, dose increase and decrease, patient monitoring, and use of folic/folinic acid.</p> <span class="elsevierStyleSectionTitle" id="sect0015">Materials and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Eleven clinical experts proposed some questions to be solved. A systematic literature search was conducted. The contents were selected in a work session and subsequently validated via email to establish the level of agreement.</p> <span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">The initial dose of methotrexate should not be &#60;10<span class="elsevierStyleHsp" style=""></span>mg/week, preferably orally, but the parenteral route is considered as an alternative due to compliance, non-effectiveness of treatment or gastrointestinal side effects, polypharmacy, obesity (if required doses are &#62;20<span class="elsevierStyleHsp" style=""></span>mg/week), patient preference, very active disease or to avoid administration errors. Changing to a parenteral administration is proposed when the oral route is not effective enough, gastrointestinal toxicity appears, there is non-compliance or due to cost-effectiveness reasons before using more expensive drugs. On the contrary, due to patient preferences, intolerance to injections, dose reduction &#60;7.5<span class="elsevierStyleHsp" style=""></span>mg/week, non-effectiveness of the route, poor compliance or gastrointestinal side effects. There should be a rapid dose escalation if inadequate responses occur up to 15&#8211;20 or even 25<span class="elsevierStyleHsp" style=""></span>mg/week in about 8 weeks, with increments of 2.5&#8211;5<span class="elsevierStyleHsp" style=""></span>mg. The reduction will be carried out according to the dose the patient had, with decreases of 2.5&#8211;5<span class="elsevierStyleHsp" style=""></span>mg every 3&#8211;6 months. Patient monitoring should be performed every 1&#8211;1.5 months until stability is reached and then for every 1&#8211;3 months.</p> <span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">This document pretends to solve some common clinical questions and facilitate decision-making in RA patients treated with methotrexate.</p>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span class="elsevierStyleSectionTitle" id="sect0035">Objetivos</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Describir la estrategia terap&eacute;utica &oacute;ptima de uso de metotrexato en AR sobre dosis inicial, v&iacute;a de administraci&oacute;n, incremento y disminuci&oacute;n de dosis, seguimiento del paciente y uso de &aacute;cido f&oacute;lico/fol&iacute;nico.</p> <span class="elsevierStyleSectionTitle" id="sect0040">Material y m&eacute;todo</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Once expertos plantearon los interrogantes cl&iacute;nicos a resolver. Se realiz&oacute; una b&uacute;squeda bibliogr&aacute;fica sistem&aacute;tica. Los contenidos fueron seleccionados en una sesi&oacute;n de trabajo y el nivel de acuerdo se estableci&oacute; posteriormente en una ronda de consenso v&iacute;a correo.</p> <span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">La dosis de inicio de metotrexato no debe ser &#60; 10 mg/semana, preferentemente por v&iacute;a oral, considerando la v&iacute;a parenteral como alternativa seg&uacute;n el cumplimento, ineficacia o efectos secundarios gastrointestinales, polimedicaci&oacute;n, obesidad (si requiere dosis &#62; 20 mg/semana), preferencias del paciente, enfermedad muy activa o para evitar errores de medicaci&oacute;n. Se cambiar&aacute; a la v&iacute;a parenteral cuando haya ineficacia, toxicidad gastrointestinal, incumplimiento o por coste-efectividad antes de pasar a f&aacute;rmacos m&aacute;s caros; y a la inversa, seg&uacute;n preferencias del paciente, intolerancia a inyectables, reducci&oacute;n de dosis &#60; 7,5 mg/semana, ineficacia, bajo cumplimiento o efectos adversos gastrointestinales. Se realizar&aacute; escalada r&aacute;pida de dosis si la respuesta es inadecuada hasta los 15-20 o, incluso, 25 mg/semana en unas 8 semanas, con incrementos de 2,5-5 mg. La reducci&oacute;n se realizar&aacute; seg&uacute;n la dosis a la que estuviera el paciente, con disminuciones de 2,5-5 mg cada 3-6 meses. El seguimiento del paciente deber&aacute; realizarse cada 1-1,5 meses hasta la estabilidad y luego cada 1-3 meses.</p> <span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Este documento pretende resolver algunos interrogantes cl&iacute;nicos habituales y facilitar la toma de decisiones en la AR tratada con metotrexato.</p>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Tornero Molina J, Ballina Garc&iacute;a FJ, Calvo Al&eacute;n J, Caracuel Ruiz M&Aacute;, Carbonell Abell&oacute; J, L&oacute;pez Meseguer A, et al. Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducci&oacute;n de dosis y v&iacute;as de administraci&oacute;n. Reumatol Clin. 2015;11:3&#8211;8.</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2094
            "Ancho" => 2491
            "Tamanyo" => 250662
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Selection of citations made from the initial search to the writing of the article.</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:1 [
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Block&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Matrix&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Screening&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Independent selection&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">1. Definitions and Interpretation. The efficacy and toxicity of DMARDs (hydroxychloroquine, and leflunomide) with MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">84&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">2. Use of aspirin at antiplatelet doses in combination with MTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">3&#8211;5. Use of MTX when desiring pregnancy, during pregnancy and lactation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">166&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">6. Use of MTX in intercurrent infection, HCV, HBV, HIV, and tuberculosis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">42&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">7. Use of MTX in minor and major surgery&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">123&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">8. MTX use in vaccination&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">9. Downscaling: in association with a biological, what should be reduced first?&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">10. MTX dose fractioning&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Total articles&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">475&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab639756.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Results of the Expanded Search for Specific Topics.</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:39 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "L.R. Lard"
                            1 => "H. Visser"
                            2 => "I. Speyer"
                            3 => "I.E. vander Horst-Bruinsma"
                            4 => "A.H. Zwinderman"
                            5 => "F.C. Breedveld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Med"
                        "fecha" => "2001"
                        "volumen" => "111"
                        "paginaInicial" => "446"
                        "paginaFinal" => "451"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11690569"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "V.P. Nell"
                            1 => "K.P. Machold"
                            2 => "G. Eberl"
                            3 => "T.A. Stamm"
                            4 => "M. Uffmann"
                            5 => "J.S. Smolen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology (Oxford)"
                        "fecha" => "2004"
                        "volumen" => "43"
                        "paginaInicial" => "906"
                        "paginaFinal" => "914"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M.A. Quinn"
                            1 => "P.G. Conaghan"
                            2 => "P. Emery"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology (Oxford)"
                        "fecha" => "2001"
                        "volumen" => "40"
                        "paginaInicial" => "1211"
                        "paginaFinal" => "1220"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J.S. Smolen"
                            1 => "R. Landewe"
                            2 => "F.C. Breedveld"
                            3 => "M. Dougados"
                            4 => "P. Emery"
                            5 => "C. Gaujoux-Viala"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2009.126532"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2010"
                        "volumen" => "69"
                        "paginaInicial" => "964"
                        "paginaFinal" => "975"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20444750"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Actualización de la guía de práctica clínica para el manejo de la artritis reumatoide en España. GuipCar 2007. Sociedad Española de Reumatología. Available from: <a href="http://www.ser.es/ArchivosDESCARGABLES/Proyectos/GUIPCAR_2007/GUIPCAR2007-Completa.pdf">http://www.ser.es/ArchivosDESCARGABLES/Proyectos/GUIPCAR_2007/GUIPCAR2007-Completa.pdf</a>"
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K.G. Saag"
                            1 => "G.G. Teng"
                            2 => "N.M. Patkar"
                            3 => "J. Anuntiyo"
                            4 => "C. Finney"
                            5 => "J.R. Curtis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23721"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "59"
                        "paginaInicial" => "762"
                        "paginaFinal" => "784"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18512708"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The use of conventional disease-modifying anti-rheumatic drugs in established RA"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M.S. Jurgens"
                            1 => "J.W. Jacobs"
                            2 => "J.W. Bijlsma"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.berh.2011.10.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Best Pract Res Clin Rheumatol"
                        "fecha" => "2011"
                        "volumen" => "25"
                        "paginaInicial" => "523"
                        "paginaFinal" => "533"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22137922"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Elaboraci&oacute;n de gu&iacute;as de pr&aacute;ctica cl&iacute;nica en el Sistema Nacional de Salud. Manual Metodol&oacute;gico"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Grupo de trabajo sobre GPC"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2007"
                        "editorial" => "Plan Nacional para el SNS del MSC, Instituto Aragonés de Ciencias de la Salud-I+CS Guías de Práctica Clínica en el SNS: I+CS no. 2006/0I"
                        "editorialLocalizacion" => "Madrid"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "SIGN 50: a guideline developers&#8217; handbook"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Scottish Intercollegiate Guidelines Network"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:3 [
                        "fecha" => "2004"
                        "editorial" => "SIGN"
                        "editorialLocalizacion" => "Edinburgh"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H.J. Williams"
                            1 => "R.F. Willkens"
                            2 => "C.O. Samuelson"
                            3 => "G.S. Alarcon"
                            4 => "M. Guttadauria"
                            5 => "C. Yarboro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "1985"
                        "volumen" => "28"
                        "paginaInicial" => "721"
                        "paginaFinal" => "730"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3893441"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of low-dose methotrexate in rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M.E. Weinblatt"
                            1 => "J.S. Coblyn"
                            2 => "D.A. Fox"
                            3 => "P.A. Fraser"
                            4 => "D.E. Holdsworth"
                            5 => "D.N. Glass"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJM198503283121303"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "1985"
                        "volumen" => "312"
                        "paginaInicial" => "818"
                        "paginaFinal" => "822"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/3883172"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "D.E. Furst"
                            1 => "R. Koehnke"
                            2 => "L.F. Burmeister"
                            3 => "J. Kohler"
                            4 => "I. Cargill"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "1989"
                        "volumen" => "16"
                        "paginaInicial" => "313"
                        "paginaFinal" => "320"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2724250"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K. Visser"
                            1 => "W. Katchamart"
                            2 => "E. Loza"
                            3 => "J.A. Martinez-Lopez"
                            4 => "C. Salliot"
                            5 => "J. Trudeau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2008.094474"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2009"
                        "volumen" => "68"
                        "paginaInicial" => "1086"
                        "paginaFinal" => "1093"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19033291"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S. Pavy"
                            1 => "A. Constantin"
                            2 => "T. Pham"
                            3 => "L. Gossec"
                            4 => "J.F. Maillefert"
                            5 => "A. Cantagrel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jbspin.2006.01.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "Joint Bone Spine"
                        "fecha" => "2006"
                        "volumen" => "73"
                        "paginaInicial" => "388"
                        "paginaFinal" => "395"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16626993"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical guidelines: developing guidelines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "P.G. Shekelle"
                            1 => "S.H. Woolf"
                            2 => "M. Eccles"
                            3 => "J. Grimshaw"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "BMJ"
                        "fecha" => "1999"
                        "volumen" => "318"
                        "paginaInicial" => "593"
                        "paginaFinal" => "596"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10037645"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "J.W. Jundt"
                            1 => "B.A. Browne"
                            2 => "G.P. Fiocco"
                            3 => "A.D. Steele"
                            4 => "D. Mock"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "1993"
                        "volumen" => "20"
                        "paginaInicial" => "1845"
                        "paginaFinal" => "1849"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8308768"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M. Hoekstra"
                            1 => "C. Haagsma"
                            2 => "C. Neef"
                            3 => "J. Proost"
                            4 => "A. Knuif"
                            5 => "M. van de Laar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2004"
                        "volumen" => "31"
                        "paginaInicial" => "645"
                        "paginaFinal" => "648"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15088287"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R.A. Hamilton"
                            1 => "J.M. Kremer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Br J Rheumatol"
                        "fecha" => "1997"
                        "volumen" => "36"
                        "paginaInicial" => "86"
                        "paginaFinal" => "90"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9117183"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S095980490300368X"
                          "estado" => "S300"
                          "issn" => "09598049"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase <span class="elsevierStyleSmallCaps">iv</span> trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J. Braun"
                            1 => "P. Kastner"
                            2 => "P. Flaxenberg"
                            3 => "J. Wahrisch"
                            4 => "P. Hanke"
                            5 => "W. Demary"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23144"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "58"
                        "paginaInicial" => "73"
                        "paginaFinal" => "81"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18163521"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J. Wegrzyn"
                            1 => "P. Adeleine"
                            2 => "P. Miossec"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2003.011593"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2004"
                        "volumen" => "63"
                        "paginaInicial" => "1232"
                        "paginaFinal" => "1234"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15361377"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A. Rozin"
                            1 => "D. Schapira"
                            2 => "A. Balbir-Gurman"
                            3 => "Y. Braun-Moscovici"
                            4 => "D. Markovits"
                            5 => "D. Militianu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2002"
                        "volumen" => "61"
                        "paginaInicial" => "756"
                        "paginaFinal" => "757"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12117691"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Improving tolerance and bioavailability of methotrexate by switching from oral to subcutaneous route of administration"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A. Breslin"
                            1 => "C. Owen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology (Oxford)"
                        "fecha" => "2005"
                        "volumen" => "44"
                        "numero" => "Suppl. 1"
                        "paginaInicial" => "i150"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Parenteral methotrexate should be given before biological therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S.J. Bingham"
                            1 => "M.H. Buch"
                            2 => "S. Lindsay"
                            3 => "A. Pollard"
                            4 => "J. White"
                            5 => "P. Emery"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology (Oxford)"
                        "fecha" => "2003"
                        "volumen" => "42"
                        "paginaInicial" => "1009"
                        "paginaFinal" => "1010"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Actualizaci&oacute;n del Documento de consenso de la Sociedad Espa&ntilde;ola de Reumatolog&iacute;a sobre el uso de terapias biol&oacute;gicas en la artritis reumatoide"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.reuma.2009.10.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Reumatol Clin"
                        "fecha" => "2010"
                        "volumen" => "6"
                        "paginaInicial" => "23"
                        "paginaFinal" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21794674"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "K. Alsufyani"
                            1 => "O. Ortiz-Alvarez"
                            2 => "D.A. Cabral"
                            3 => "L.B. Tucker"
                            4 => "R.E. Petty"
                            5 => "P.N. Malleson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "J Rheumatol"
                        "fecha" => "2004"
                        "volumen" => "31"
                        "paginaInicial" => "179"
                        "paginaFinal" => "182"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14705239"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Subcutaneous methotrexate is an effective alternative to biologic agents: results of a review of service provided"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "K. Lindsay"
                            1 => "S. Shiela"
                            2 => "H. Lesley"
                            3 => "M. Sarah"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology (Oxford)"
                        "fecha" => "2006"
                        "volumen" => "45"
                        "numero" => "Suppl. 1"
                        "paginaInicial" => "i124"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tolerability of methotrexate starting with 15 or 25<span class="elsevierStyleHsp" style=""></span>mg/week for rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A. Schnabel"
                            1 => "E. Reinhold-Keller"
                            2 => "V. Willmann"
                            3 => "W.L. Gross"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatol Int"
                        "fecha" => "1994"
                        "volumen" => "14"
                        "paginaInicial" => "33"
                        "paginaFinal" => "38"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7939138"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial)"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S.M. Verstappen"
                            1 => "J.W. Jacobs"
                            2 => "M.J. van der Veen"
                            3 => "A.H. Heurkens"
                            4 => "Y. Schenk"
                            5 => "E.J. Ter Borg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2007.071092"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2007"
                        "volumen" => "66"
                        "paginaInicial" => "1443"
                        "paginaFinal" => "1449"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17519278"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Methotrexate in rheumatoid arthritis, starting dose and dose escalation regimens"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "I.A.H. Jassim"
                            1 => "A. Al-Allaf"
                            2 => "P. Newton"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2007"
                        "volumen" => "66"
                        "paginaInicial" => "S440"
                        "paginaFinal" => "S441"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C.M. Lambert"
                            1 => "S. Sandhu"
                            2 => "A. Lochhead"
                            3 => "N.P. Hurst"
                            4 => "E. McRorie"
                            5 => "V. Dhillon"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.20167"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2004"
                        "volumen" => "50"
                        "paginaInicial" => "364"
                        "paginaFinal" => "371"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14872477"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis. A post hoc analysis of the CAMERA study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M.F. Bakker"
                            1 => "J.W.G. Jacobs"
                            2 => "P.M.J. Welsing"
                            3 => "J.H. van der Werf"
                            4 => "S.P. Linn-Rasker"
                            5 => "M.J. van der Veen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/ard.2009.124065"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis"
                        "fecha" => "2010"
                        "volumen" => "69"
                        "paginaInicial" => "1849"
                        "paginaFinal" => "1852"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20511610"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J.W. Jacobs"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatology (Oxford)"
                        "fecha" => "2012"
                        "volumen" => "51"
                        "numero" => "Suppl. 4"
                        "paginaInicial" => "iv3"
                        "paginaFinal" => "iv8"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Levels of evidence"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "Oxford Centre for Evidence-Based Medicine"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Libro" => array:1 [
                        "fecha" => "2009"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Y.P.M. Goekoop-Ruiterman"
                            1 => "J.K. de Vries-Bouwstra"
                            2 => "C.F. Allaart"
                            3 => "D. van Zeben"
                            4 => "P.J.S.M. Kerstens"
                            5 => "J.M.W. Hazes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21405"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2005"
                        "volumen" => "52"
                        "paginaInicial" => "3381"
                        "paginaFinal" => "3390"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16258899"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C. Grigor"
                            1 => "H. Capell"
                            2 => "A. Stirling"
                            3 => "A.D. McMahon"
                            4 => "P. Lock"
                            5 => "R. Vallance"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(04)16676-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2004"
                        "volumen" => "364"
                        "paginaInicial" => "263"
                        "paginaFinal" => "269"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15262104"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:1 [
                      "titulo" => "Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology ad hoc committee on clinical guidelines"
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "1996"
                        "volumen" => "39"
                        "paginaInicial" => "723"
                        "paginaFinal" => "731"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8639168"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J.S. Gao"
                            1 => "H. Wu"
                            2 => "J. Tian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Zhonghua Er Ke Za Zhi"
                        "fecha" => "2003"
                        "volumen" => "41"
                        "paginaInicial" => "435"
                        "paginaFinal" => "438"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14748999"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "T. Niehues"
                            1 => "G. Horneff"
                            2 => "H. Michels"
                            3 => "M.S. Hock"
                            4 => "L. Schuchmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00296-004-0537-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rheumatol Int"
                        "fecha" => "2005"
                        "volumen" => "25"
                        "paginaInicial" => "169"
                        "paginaFinal" => "178"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15688190"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A.E. Van Ede"
                            1 => "R.F. Laan"
                            2 => "M.J. Rood"
                            3 => "T.W. Huizinga"
                            4 => "M.A. van de Laar"
                            5 => "C.J. van Denderen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2001"
                        "volumen" => "44"
                        "paginaInicial" => "1515"
                        "paginaFinal" => "1524"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11465701"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack121433"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0255" class="elsevierStylePara elsevierViewall">We thank Manel Alepuz and Veronica Albert, of Gesti&oacute; Organitzaci&oacute; Comunicaci&oacute;, SA for their support in conducting the methodology used to prepare the study.</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735743/0000001100000001/v1_201501160858/S2173574314000872/v1_201501160858/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "5793"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Special article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001100000001/v1_201501160858/S2173574314000872/v1_201501160858/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574314000872?idApp=UINPBA00004M"
]

Article information

ISSN: 21735743
Original language: English

DOI:10.1016/j.reumae.2014.02.006

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 October	332	60	392
2024 September	395	54	449
2024 August	393	47	440
2024 July	471	75	546
2024 June	389	69	458
2024 May	374	39	413
2024 April	327	72	399
2024 March	2333	84	2417
2024 February	445	51	496
2024 January	407	43	450
2023 December	329	67	396
2023 November	373	95	468
2023 October	590	76	666
2023 September	489	65	554
2023 August	514	77	591
2023 July	509	52	561
2023 June	431	58	489
2023 May	469	50	519
2023 April	363	61	424
2023 March	679	75	754
2023 February	493	58	551
2023 January	579	41	620
2022 December	536	82	618
2022 November	510	70	580
2022 October	460	83	543
2022 September	405	52	457
2022 August	352	84	436
2022 July	310	91	401
2022 June	383	91	474
2022 May	488	76	564
2022 April	512	90	602
2022 March	572	118	690
2022 February	541	88	629
2022 January	636	147	783
2021 December	668	83	751
2021 November	480	74	554
2021 October	615	78	693
2021 September	465	77	542
2021 August	521	76	597
2021 July	327	77	404
2021 June	478	81	559
2021 May	456	54	510
2021 April	1428	162	1590
2021 March	956	94	1050
2021 February	1202	73	1275
2021 January	1146	93	1239
2020 December	1017	71	1088
2020 November	735	54	789
2020 October	618	25	643
2020 September	774	65	839
2020 August	667	42	709
2020 July	834	35	869
2020 June	449	46	495
2020 May	392	54	446
2020 April	448	40	488
2020 March	127	14	141
2020 February	2	0	2
2019 April	3	2	5
2018 May	4	1	5
2018 April	69	21	90
2018 March	79	13	92
2018 February	57	14	71
2018 January	45	9	54
2017 December	58	12	70
2017 November	63	17	80
2017 October	52	21	73
2017 September	82	26	108
2017 August	66	19	85
2017 July	97	17	114
2017 June	124	28	152
2017 May	148	23	171
2017 April	124	12	136
2017 March	114	20	134
2017 February	86	20	106
2017 January	78	18	96
2016 December	133	29	162
2016 November	131	10	141
2016 October	139	18	157
2016 September	225	19	244
2016 August	110	9	119
2016 July	62	6	68
2016 January	1	0	1
2015 December	2	0	2
2015 September	2	0	2
2015 August	1	0	1
2015 July	35	19	54
2015 June	89	34	123
2015 May	120	26	146
2015 April	137	24	161
2015 March	115	31	146
2015 February	114	44	158
2015 January	95	18	113

Show all

Indexed in:

Follow us:

Subscribe:

Statistics

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter